Acetylene derivatives having lipoxygenase inhibitory activity
AssigneeAbbott Laboratories
InventorsDee W. Brooks, Andrew O. Stewart, Daniel J. Kerkman, Pramila A. Bhatia, Anwer Basha, Jonathan G. Martin
Life of this patent
Estimating the term…
Loading patent…
AssigneeAbbott Laboratories
InventorsDee W. Brooks, Andrew O. Stewart, Daniel J. Kerkman, Pramila A. Bhatia, Anwer Basha, Jonathan G. Martin
Estimating the term…
Compounds of the structure ##STR1## where p and q are zero or one, but cannot both be the same, M is a pharmaceutically acceptable cation or a metabolically cleavable group, B is a valence bond or a straight or branched alkylene group, R is alkyl, cycloalkyl or --NR.sup.1 R.sup.2, where R.sup.1 and R.sup.2 are hydrogen, alkyl, cycloalkyl or alkanoyl, and A is optionally substituted carbocyclic aryl, furyl, benzo[b]furyl, thienyl, or benzo[b]thienyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.
A compound having the structure ##STR14## wherein B is a valence bond or is a straight or branched divalent alkylene group of one to twelve carbon atoms,
A compound, or pharmaceutically acceptable salt thereof, having the name N-hydroxy-N-(4-(3-(4-fluorophenoxy)phenyl)-3-butyn-2-yl)urea.
A compound, or pharmaceutically acceptable salt thereof, having the name (+)-N-hydroxy-N-(4-(3-(4-fluorophenoxy)phenyl)-3-butyn-2-yl)urea.
A compound, or pharmaceutically acceptable salt thereof, having the name (-)-N-hydroxy-N-(4-(3-(4-fluorophenoxy )phenyl)-3-butyn-2-yl)urea.
Dependencies are inferred from the claim text.